The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Treatment outcome according to tumor RAS mutation status in OPUS study patients with metastatic colorectal cancer (mCRC) randomized to FOLFOX4 with/without cetuximab.
Carsten Bokemeyer
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
Claus-Henning Kohne
Consultant or Advisory Role - EMA (London)
Honoraria - Bayer; Bristol-Myers Squibb; Merck KGaA; Roche
Fortunato Ciardiello
Honoraria - Bayer; Merck Serono
Research Funding - AstraZeneca; Bayer; Merck Serono
Heinz-Josef Lenz
Consultant or Advisory Role - Bristol-Myers Squibb; EMD Serono; Merck KGaA
Honoraria - Bristol-Myers Squibb; EMD Serono; Merck KGaA
Research Funding - Bristol-Myers Squibb; EMD Serono
Volker Heinemann
Consultant or Advisory Role - Amgen; Merck KGaA; Roche; Sanofi
Honoraria - Amgen; Merck KGaA; Roche; Sanofi
Research Funding - Amgen; Merck KGaA; Roche; Sanofi
Ute Klinkhardt
Employment or Leadership Position - Merck KGaA
Frank Beier
Employment or Leadership Position - Merck KGaA
Klaus Duecker
Employment or Leadership Position - Merck Serono
Other Remuneration - Merck Serono
Sabine Tejpar
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono